Form 4: Elicio Therapeutics Executive Acquires Stock Options

Preetam Shah, Chief Strategy and Financial Officer of Elicio Therapeutics, acquired stock options for 191,624 shares of common stock on April 15, 2025.

Summary

• On April 15, 2025, Preetam Shah, the Chief Strategy and Financial Officer of Elicio Therapeutics, acquired stock options.
• These options grant the right to buy 191,624 shares of Elicio Therapeutics common stock at an exercise price of $4.98 per share.
• The options vest over a period of three years, starting with 25% vesting on March 24, 2025, and the remainder vesting in equal monthly installments thereafter, contingent upon continued service to the company.
• The options expire on April 15, 2035.

Sentiment

Score: 7

Explanation: The granting of stock options is generally viewed positively as it aligns executive interests with shareholder value. The vesting schedule promotes long-term commitment.

Positives

• The acquisition of stock options by a key executive signals confidence in the company's future prospects.

Future Outlook

The vesting schedule of the options incentivizes the executive to remain with the company for the next three years.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to improve company performance.
• The executive is incentivized to remain with the company and contribute to its success.

Key Dates

Keywords

stock options, Elicio Therapeutics, Preetam Shah, Form 4, executive compensation, ELTX